Aktuelle Therapieansätze beim malignen Melanom mit leptomeningealer Metastasierung

Julian Steininger; Isabella C. Glitza Oliva

doi:10.1007/s11654-022-00365-9

Aktuelle Therapieansätze beim malignen Melanom mit leptomeningealer Metastasierung

Translated title of the contribution: Current therapeutic approaches in malignant melanoma patients with leptomeningeal disease

Julian Steininger, Isabella C. Glitza Oliva

Melanoma Medical Oncology

Research output: Contribution to journal › Review article › peer-review

Abstract

Despite fundamental advances in the field of oncology, the prognosis of leptomeningeal metastasis (LMD) remains poor, with the average overall survival typically measured in weeks to a few months. Malignant melanoma (MM) is one of the solid malignancies with the highest tendency to metastasize to this space: approximately 10–15% of patients with advanced MM develop LMD. In addition to diagnostic challenges, the incidence of LMD appears to be rising; currently available treatment options appear to have very little impact on survival. This review provides a short overview of the epidemiology, diagnosis, and current treatment approaches for MM patients with LMD. Finally, currently ongoing clinical trials are briefly reviewed, for which promising and trendsetting results have already been presented.

Translated title of the contribution	Current therapeutic approaches in malignant melanoma patients with leptomeningeal disease
Original language	German
Pages (from-to)	96-102
Number of pages	7
Journal	Best Practice Onkologie
Volume	17
Issue number	3
DOIs	https://doi.org/10.1007/s11654-022-00365-9
State	Published - Mar 2022

Keywords

CNS microenvironment
Intrathecal therapy
Leptomeningeal carcinomatosis
Leptomeningeal disease
Melanoma

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s11654-022-00365-9

Cite this

@article{b23896273c5b4277b127daf49853ea5b,

title = "Aktuelle Therapieans{\"a}tze beim malignen Melanom mit leptomeningealer Metastasierung",

abstract = "Despite fundamental advances in the field of oncology, the prognosis of leptomeningeal metastasis (LMD) remains poor, with the average overall survival typically measured in weeks to a few months. Malignant melanoma (MM) is one of the solid malignancies with the highest tendency to metastasize to this space: approximately 10–15% of patients with advanced MM develop LMD. In addition to diagnostic challenges, the incidence of LMD appears to be rising; currently available treatment options appear to have very little impact on survival. This review provides a short overview of the epidemiology, diagnosis, and current treatment approaches for MM patients with LMD. Finally, currently ongoing clinical trials are briefly reviewed, for which promising and trendsetting results have already been presented.",

keywords = "CNS microenvironment, Intrathecal therapy, Leptomeningeal carcinomatosis, Leptomeningeal disease, Melanoma",

author = "Julian Steininger and {Glitza Oliva}, {Isabella C.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2022",

month = mar,

doi = "10.1007/s11654-022-00365-9",

language = "German",

volume = "17",

pages = "96--102",

journal = "Best Practice Onkologie",

issn = "0946-4565",

publisher = "Springer Verlag",

number = "3",

}

TY - JOUR

T1 - Aktuelle Therapieansätze beim malignen Melanom mit leptomeningealer Metastasierung

AU - Steininger, Julian

AU - Glitza Oliva, Isabella C.

PY - 2022/3

Y1 - 2022/3

N2 - Despite fundamental advances in the field of oncology, the prognosis of leptomeningeal metastasis (LMD) remains poor, with the average overall survival typically measured in weeks to a few months. Malignant melanoma (MM) is one of the solid malignancies with the highest tendency to metastasize to this space: approximately 10–15% of patients with advanced MM develop LMD. In addition to diagnostic challenges, the incidence of LMD appears to be rising; currently available treatment options appear to have very little impact on survival. This review provides a short overview of the epidemiology, diagnosis, and current treatment approaches for MM patients with LMD. Finally, currently ongoing clinical trials are briefly reviewed, for which promising and trendsetting results have already been presented.

AB - Despite fundamental advances in the field of oncology, the prognosis of leptomeningeal metastasis (LMD) remains poor, with the average overall survival typically measured in weeks to a few months. Malignant melanoma (MM) is one of the solid malignancies with the highest tendency to metastasize to this space: approximately 10–15% of patients with advanced MM develop LMD. In addition to diagnostic challenges, the incidence of LMD appears to be rising; currently available treatment options appear to have very little impact on survival. This review provides a short overview of the epidemiology, diagnosis, and current treatment approaches for MM patients with LMD. Finally, currently ongoing clinical trials are briefly reviewed, for which promising and trendsetting results have already been presented.

KW - CNS microenvironment

KW - Intrathecal therapy

KW - Leptomeningeal carcinomatosis

KW - Leptomeningeal disease

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=85123569094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123569094&partnerID=8YFLogxK

U2 - 10.1007/s11654-022-00365-9

DO - 10.1007/s11654-022-00365-9

M3 - Review article

AN - SCOPUS:85123569094

SN - 0946-4565

VL - 17

SP - 96

EP - 102

JO - Best Practice Onkologie

JF - Best Practice Onkologie

IS - 3

ER -

Aktuelle Therapieansätze beim malignen Melanom mit leptomeningealer Metastasierung

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this